Medpace (NASDAQ:MEDP) Shares Up 0.6%

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report)'s share price shot up 0.6% during mid-day trading on Thursday . The stock traded as high as $402.11 and last traded at $400.11. 52,823 shares were traded during trading, a decline of 79% from the average session volume of 248,554 shares. The stock had previously closed at $397.86.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MEDP. Jefferies Financial Group upgraded Medpace from a "hold" rating to a "buy" rating and lifted their price target for the company from $340.00 to $450.00 in a report on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft initiated coverage on Medpace in a report on Monday, March 18th. They set a "hold" rating and a $395.00 price target for the company. StockNews.com upgraded Medpace from a "hold" rating to a "buy" rating in a report on Tuesday, April 23rd. Robert W. Baird boosted their target price on Medpace from $446.00 to $454.00 and gave the stock an "outperform" rating in a report on Wednesday, April 24th. Finally, UBS Group upgraded Medpace from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $443.00.

Medpace Trading Down 1.7 %

The firm has a market cap of $12.12 billion, a price-to-earnings ratio of 39.86, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40. The company has a 50 day moving average of $398.27 and a 200 day moving average of $329.37.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts' consensus estimates of $2.45 by $0.75. The company had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business's revenue was up 17.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.27 earnings per share. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 102 shares of the company's stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the transaction, the vice president now owns 15,181 shares of the company's stock, valued at $6,117,943. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO August J. Troendle sold 100,000 shares of the company's stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the sale, the chief executive officer now owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Susan E. Burwig sold 102 shares of the company's stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the sale, the vice president now owns 15,181 shares of the company's stock, valued at approximately $6,117,943. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 204,442 shares of company stock valued at $82,702,867. 20.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Medpace

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Medpace by 5.9% in the fourth quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company's stock valued at $783,626,000 after purchasing an additional 142,591 shares during the last quarter. Riverbridge Partners LLC increased its holdings in Medpace by 7.1% in the fourth quarter. Riverbridge Partners LLC now owns 652,384 shares of the company's stock valued at $199,975,000 after purchasing an additional 43,197 shares during the last quarter. Invesco Ltd. increased its holdings in Medpace by 67.6% in the third quarter. Invesco Ltd. now owns 611,900 shares of the company's stock valued at $148,159,000 after purchasing an additional 246,775 shares during the last quarter. TD Asset Management Inc increased its holdings in Medpace by 195.2% in the fourth quarter. TD Asset Management Inc now owns 467,041 shares of the company's stock valued at $143,162,000 after purchasing an additional 308,816 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in Medpace by 312.6% in the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company's stock valued at $102,013,000 after purchasing an additional 319,210 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.